Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Schwind

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|January 31, 2017
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantationMadlen Jentzsch, Marius Bill, Deedra Nicolet, et al.
Haematologica|June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germlineJason H Mendler, Kati Maharry, Heiko Becker, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Journal of Cancer Research and Clinical Oncology|August 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)Juliane Beck, Andreas Schwarzer, Dietrich Gläser, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Bone Marrow Transplantation|June 3, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-CellsSimon M Krauß, Konstantin Weibl, Enrica Bach, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|January 31, 2017
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantationMadlen Jentzsch, Marius Bill, Deedra Nicolet, et al.
Haematologica|June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germlineJason H Mendler, Kati Maharry, Heiko Becker, et al.
Oncotarget|August 13, 2016
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Ramasamy Santhanam, et al.
The AAPS Journal|November 27, 2012
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaHongyan Wang, Ping Chen, Jiang Wang, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Journal of Cancer Research and Clinical Oncology|August 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)Juliane Beck, Andreas Schwarzer, Dietrich Gläser, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Bone Marrow Transplantation|June 3, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-CellsSimon M Krauß, Konstantin Weibl, Enrica Bach, et al.
Pageof 11